Mode
Text Size
Log in / Sign up

Alert-based CDS increases UACR testing from 11.5% to 36.0% in patients with type 2 diabetesComputer alerts help doctors find kidney issues in diabetes patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that alert-based CDS significantly increases UACR testing rates and identification of elevated albuminuria in T2D.

This randomized clinical trial enrolled 400 outpatients with type 2 diabetes who had not undergone UACR testing in the prior 12 months and had no chronic kidney disease. The study compared an electronic alert-based computerized decision support (CDS) system against a control group with no alert.

The primary outcome was the proportion of UACR orders within 90 days. The alert group showed a significantly higher rate of orders at 36.0% (72 patients) compared to 11.5% (23 patients) in the control group (OR 5.71; 95% CI 2.58-12.64; P < 0.001). Post-hoc analyses showed higher rates of UACR ≥10 mg/g (21.0% vs. 8.5%, OR 3.41, P = 0.008) and UACR ≥30 mg/g (9.5% vs. 4.0%, OR 3.71, P = 0.011) in the alert group.

Secondary outcomes, including new diagnoses of chronic kidney disease stage 3-5, referrals to a nephrologist, and prescriptions of chronic kidney disease-related medications, showed no significant differences between groups. No adverse events or discontinuations were reported. The study is limited by the post-hoc nature of the albuminuria detection outcomes. The alert-based CDS is associated with increased UACR testing and identification of elevated albuminuria in patients with diabetes.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in the management of type 2 diabetes by focusing on the diagnostic workflow for kidney disease. While prior coverage established that GLP-1 receptor agonists and Tirzepatide reduce MACE in patients with type 2 diabetes, this study focuses on the identification of albuminuria through CDS. It does not directly relate to the findings regarding early time-restricted eating, low fat-free mass metrics, or high-risk adiposity and inflammation trajectories.

Managing type 2 diabetes often involves keeping a close watch on kidney health. However, some patients may not get the necessary tests to catch early signs of damage. This study looked at how a simple computer alert could change how doctors manage these patients.

Researchers gave 400 patients with type 2 diabetes a computerized decision support tool. This tool sent an alert to doctors to order a specific kidney test called UACR. In the group that received the alert, 36% of patients received the test within 90 days, compared to only 11.5% in the group without the alert. This jump suggests that a simple digital nudge can help doctors catch potential issues much faster.

While the alert led to more testing and helped identify more cases of high protein in the urine, it did not lead to more new diagnoses of advanced kidney disease or more specialist referrals during the study period. Because some of the findings regarding high protein levels were analyzed after the study was finished, these specific results should be viewed with some caution.

What this means for you:
Computer alerts can significantly increase the number of kidney tests ordered for patients with type 2 diabetes.

Common questions

How did the computer alert help patients with diabetes?

The alert prompted doctors to order a UACR test, which checks for protein in the urine. In the group with the alert, 36% of patients received this test within 90 days, while only 11.5% of patients in the group without the alert received it.

Did the alert lead to more advanced kidney disease diagnoses?

The study did not find a significant difference in the number of new diagnoses for advanced kidney disease (stages 3-5) between the group that received the alert and the group that did not.

What specific kidney issues did the alert help identify?

The alert helped identify more cases of elevated albuminuria, which is a high level of protein in the urine. Specifically, 21% of the alert group had a UACR of 10 mg/g or higher, compared to 8.5% in the group without the alert.

Study Details

Study typeRct
Sample sizen = 400
EvidenceLevel 2
Follow-up216.0 mo
PublishedSep 2026
View Original Abstract ↓
BACKGROUND: Urine albumin-to-creatinine ratio (UACR) provides a reliable method for chronic kidney disease screening in patients with type 2 diabetes, yet its use remains underutilized. METHODS: The CKD-DETECT randomized clinical trial included outpatients ≥18 years with type 2 diabetes without UACR testing in the prior 12 months and no chronic kidney disease. Physicians were randomized to receive either an alert prompting UACR testing or no alert (control). The primary outcome was the proportion of UACR orders within 90 days. The secondary outcome was new chronic kidney disease stage 3-5 diagnoses. Tertiary outcomes were referral to a nephrologist and prescription of chronic kidney disease-related medications, and post-hoc outcomes were UACR ≥10 mg/g and ≥30 mg/g. RESULTS: Overall, 400 patients (mean age 64.7 years; 51.5% female) were included. UACR was ordered in 72 (36.0%) patients in the alert group vs. 23 (11.5%) in the control group (odds ratio [OR] 5.71; 95% confidence interval [CI] 2.58-12.64; P < 0.001). New diagnoses of chronic kidney disease occurred in 1 (0.5%) patient in the alert and 2 (1.0%) in the control group (OR 0.50, 95%CI 0.04-5.53; P = 0.570). There were no referrals to nephrologists or new prescriptions of chronic kidney disease-related medications. The alert group was associated with increased identification of UACR ≥10 mg/g (21.0% vs. 8.5%; OR 3.41; 95%CI 1.37-8.48; P = 0.008) and ≥30 mg/g (9.5% vs. 4.0%; OR 3.71; 95%CI 1.36-10.12; P = 0.011). CONCLUSION: The alert-based CDS program was associated with increased UACR testing and early detection of elevated albuminuria in patients with diabetes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT05342545 (prospectively registered on April 18, 2022) FUNDING: This work was supported by a research grant from Bayer.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.